A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases

Hannah C. Moore; Jeffrey W. Cannon; David C. Kaslow; Theresa Lamagni; Asha C. Bowen; Kate M. Miller; Thomas Cherian; Jonathan Carapetis; Chris Van Beneden

doi:10.1093/cid/ciac291

A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases

Hannah C. Moore^*, Jeffrey W. Cannon, David C. Kaslow, Theresa Lamagni, Asha C. Bowen, Kate M. Miller, Thomas Cherian, Jonathan Carapetis, Chris Van Beneden

^*Corresponding author for this work

AMR NAP: Human infection prevention and control

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives - advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing - and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.

Original language	English
Pages (from-to)	1245-1254
Number of pages	10
Journal	Clinical Infectious Diseases
Volume	75
Issue number	7
DOIs	https://doi.org/10.1093/cid/ciac291
Publication status	Published - 1 Oct 2022

Bibliographical note

Funding Information:
Potential conflicts of interest. H. C. M. has received funding from Merck, Sharp and Dohme under the Merck Investigator Studies Program (not related to the work presented in this article). D. C. K. reports an unpaid volunteer leadership or fiduciary role on the WHO Product Development for Vaccines Advisory Committee, Leducq Foundation Scientific Advisory Board, and SAVAC Executive Committee. All other authors report no potential conflicts.

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Keywords

burden of disease
group A streptococcal diseases
vaccine development
vaccine policy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciac291

Cite this

Moore, H. C., Cannon, J. W., Kaslow, D. C., Lamagni, T., Bowen, A. C., Miller, K. M., Cherian, T., Carapetis, J., & Van Beneden, C. (2022). A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases. Clinical Infectious Diseases, 75(7), 1245-1254. https://doi.org/10.1093/cid/ciac291

@article{6d6a74c9659e45f8acb1f74324384491,

title = "A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases",

abstract = "Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives - advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing - and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.",

keywords = "burden of disease, group A streptococcal diseases, vaccine development, vaccine policy",

author = "Moore, {Hannah C.} and Cannon, {Jeffrey W.} and Kaslow, {David C.} and Theresa Lamagni and Bowen, {Asha C.} and Miller, {Kate M.} and Thomas Cherian and Jonathan Carapetis and {Van Beneden}, Chris",

note = "Funding Information: Potential conflicts of interest. H. C. M. has received funding from Merck, Sharp and Dohme under the Merck Investigator Studies Program (not related to the work presented in this article). D. C. K. reports an unpaid volunteer leadership or fiduciary role on the WHO Product Development for Vaccines Advisory Committee, Leducq Foundation Scientific Advisory Board, and SAVAC Executive Committee. All other authors report no potential conflicts. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of the Infectious Diseases Society of America.",

year = "2022",

month = oct,

day = "1",

doi = "10.1093/cid/ciac291",

language = "English",

volume = "75",

pages = "1245--1254",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

Moore, HC, Cannon, JW, Kaslow, DC, Lamagni, T, Bowen, AC, Miller, KM, Cherian, T, Carapetis, J & Van Beneden, C 2022, 'A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases', Clinical Infectious Diseases, vol. 75, no. 7, pp. 1245-1254. https://doi.org/10.1093/cid/ciac291

TY - JOUR

T1 - A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation

T2 - The Case for Group A Streptococcal Diseases

AU - Moore, Hannah C.

AU - Cannon, Jeffrey W.

AU - Kaslow, David C.

AU - Lamagni, Theresa

AU - Bowen, Asha C.

AU - Miller, Kate M.

AU - Cherian, Thomas

AU - Carapetis, Jonathan

AU - Van Beneden, Chris

N1 - Funding Information: Potential conflicts of interest. H. C. M. has received funding from Merck, Sharp and Dohme under the Merck Investigator Studies Program (not related to the work presented in this article). D. C. K. reports an unpaid volunteer leadership or fiduciary role on the WHO Product Development for Vaccines Advisory Committee, Leducq Foundation Scientific Advisory Board, and SAVAC Executive Committee. All other authors report no potential conflicts. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives - advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing - and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.

AB - Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives - advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing - and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.

KW - burden of disease

KW - group A streptococcal diseases

KW - vaccine development

KW - vaccine policy

UR - http://www.scopus.com/inward/record.url?scp=85139535721&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac291

DO - 10.1093/cid/ciac291

M3 - Article

C2 - 35438130

AN - SCOPUS:85139535721

SN - 1058-4838

VL - 75

SP - 1245

EP - 1254

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this